Hepatotoxicity of statins and other lipid-lowering agents

Liver International

Volumn 37, Issue 2, 2017, Pages 173-178

  Björnsson, Einar S ^a,b  

^a LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^b UNIVERSITY OF ICELAND   (Iceland)

Author keywords

atorvastatin; drug induced liver injury; hepatotoxicity; simvastatin; statins

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

CHRONICITY; HUMAN; LIVER HISTOLOGY; LIVER TOXICITY; LIVER TRANSPLANTATION; MORTALITY; PHENOTYPE; REVIEW; TOXIC HEPATITIS; TREATMENT DURATION; TREATMENT OUTCOME;

ATORVASTATIN CALCIUM; CHEMICAL AND DRUG INDUCED LIVER INJURY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; SIMVASTATIN;

EID: 85005808117     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13308     Document Type: Review

References (50)

1. Pedersen TR, Kjekshus J, Berg K, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389.
2. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med. 1999;151:43–49.
3. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711–1718.
4. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301–1307.
5. Senior JR. Evolution of the Food and Drug Administration approach to liver safety assessment for new drugs: current status and challenges. Drug Saf. 2014;37(Suppl 1):S9–S17.
6. Feydy P, Bogomoletz WV. A case of hepatitis caused by simvastatin [French]. Gastroenterol Clin Biol. 1991;15:94–95.
7. Ballare M, Campanini M, Catania E, Bordin G, Zaccala G, Monteverde A. Acute cholestatic hepatitis during simvastatin administration. Recenti Prog Med. 1991;82:233–235.
8. England JD, Viles A, Labib S. Liver side effects associated with simvastatin therapy. Med J Aust. 1991;155:61.
9. Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005;42:481–489.
10. Andrade RJ, Lucena MI, Fernández MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Spanish Group for the Study of Drug-Induced Liver Disease. Gastroenterology. 2005;129:512–521.
11. Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Drug Induced Liver Injury Network (DILIN). Gastroenterology. 2008;135:1924–1934.
12. Devarbhavi H, Dierkhising R, Kremers WK, et al. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol. 2010;105:2396–2404.
13. Idilman R, Bektas M, Cinar K, et al. The characteristics and clinical outcome of drug-induced liver injury: a single-center experience. J Clin Gastroenterol. 2010;44:128–132.
14. Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144:1419–1425.
15. Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology. 2015;148:1340–1352.
16. Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Review. Semin Liver Dis. 2009;29:412–422.
17. Reuben A, Koch DG, Lee WM. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology. 2010;52:2065–2076.
18. Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012;56:374–380.
19. Perdices EV, Medina-Cáliz I, Hernando S, et al. Hepatotoxicity associated with statin use: analysis of the cases included in the Spanish Hepatotoxicity Registry. Rev Esp Enferm Dig. 2014;106:246–254.
20. Russo MW, Hoofnagle JH, Gu J, et al. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology. 2014;60:679–686.
21. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004;126:1287–1292.
22. Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Belder R. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology. 2007;46:1453–1463.
23. Bergmann OM, Kristjansson G, Jonasson JG, Björnsson ES. Jaundice Due to Suspected Statin Hepatotoxicity: a Case Series. Dig Dis Sci. 2012;57:1959–1964.
24. Charles EC, Olson KL, Sandhoff BG, McClure DL, Merenich JA. Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. Am J Med. 2005;118:618–624.
25. Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 2004;10:1018–1023.
26. Carrascosa MF, Salcines-Caviedes JR, Isabel Lucena M, Andrade RJ. Acute liver failure following atorvastatin dose escalation: is there athreshold dose for idiosyncratic hepatotoxicity? J Hepatol 2015;62:739–752.
27. Lammert C, Einarsson S, Niklasson A, Bjornsson E, Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury (DILI): search for signals. Hepatology. 2008;47:2003–2009.
28. Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology. 2013;58:388–396.
29. Lammert C, Niklasson A, Saha C, Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology. 2010;51:615–620.
30. Sreenarasimhaiah J, Shiels P, Lisker-Melman M. Multiorgan failure induced by atorvastatin. Am J Med. 2002;113:348–349.
31. Batey RG, Harvey M. Cholestasis associated with the use of pravastatin sodium. Med J Aust. 2002;176:561.
32. Björnsson E, Talwalkar J, Treeprasertsuk S, et al. Drug-induced Autoimmune Hepatitis: clinical characteristics and prognosis. Hepatology. 2010;51:2040–2048.
33. Björnsson ES, Gunnarsson BI, Gröndal G, et al. The risk of drug-induced liver injury from Tumor Necrosis Factor (TNF)-alpha-antagonists. Clin Gastroenterol Hepatol. 2015;13:602–608.
34. Jiménez-Alonso J, Osorio JM, Gutiérrez-Cabello F, et al. Atorvastatin-induced cholestatic hepatitis in a young woman with systemic lupus erythematosus. Grupo Lupus Virgen de las Nieves. Arch Intern Med. 1999;159:1811–1812.
35. Pelli N, Setti M, Ceppa P, Toncini C, Indiveri F. Autoimmune hepatitis revealed by atorvastatin. Eur J Gastroenterol Hepatol. 2003;15:921–924.
36. Van Heyningen C. Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe. Curr Opin Lipidol. 2005;16:597–599.
37. Alla V, Abraham J, Siddiqui J, et al. Autoimmune hepatitis triggered by statins. J Clin Gastroenterol. 2006;40:757–761.
38. Lucena MI, Kaplowitz N, Hallal H, et al. Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis. J Hepatol. 2011;55:820–827.
39. Medina-Caliz I, Robles-Diaz M, Garcia-Muñoz B, et al. Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. J Hepatol 2016;63:532–542.
40. Björnsson ES, Hoofnagle JH. Categorization of drugs implicated in causing liver injury: critical assessment based upon published case reports. Hepatology. 2016;63:590–603.
41. Perger L, Kohler M, Fattinger K, Flury R, Meier PJ, Pauli-Magnus C. Fatal liver failure with atorvastatin. J Hepatol. 2003;39:1095–1097.
42. Clarke AT, Mills PR. Atorvastatin associated liver disease. Dig Liver Dis. 2006;38:772–777.
43. Rivin AU. Jaundice occurring during nicotinic acid therapy for hypercholesterolemia. JAMA. 1959;170:2088–2089.
44. Patterson DJ, Dew EW, Gyorkey F, Graham DY. Niacin hepatitis. South Med J. 1983;76:239–241.
45. Sugerman AA, Clark CG. Jaundice following the administration of niacin. JAMA. 1974;228:202.
46. Rourk RM, Rehman NU. Niacin. Help for your cholesterol–harm for your liver. N C Med J. 1998;59:87–88.
47. Punthakee Z, Scully LJ, Cuindi MM, Ooi TC. Liver fibrosis attributed to lipid lowering medications: two cases. J Intern Med. 2001;150:249–254.
48. Bustamante Balén M, Plumé Gimeno G, Bau González I, Berenguer Lapuerta J. Acute hepatitis caused by gemfibrozil. Gastroenterol Hepatol 1998;21:419–420.
49. Pierce EH, Chesler DL. Possible association of granulomatous hepatitis with clofibrate therapy. N Engl J Med. 1978;299:314.
50. Andrade RJ, Lucena IM, Kaplowitz N, et al. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology. 2006;44:1581–1588.